Close

TS-Fluc Anti-PD-L1 (Atezolizumab) 28ζ CAR (XS-0722-YF56)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-Human PD-L1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells. The receptor construction is 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ. 7H-YB means seven repeats of the HSE motif 5'-nGAAnnTTCnnGAAn-3' upstream of the human synthetic core promoter (YB). 7H-YB is a technology for photothermal control of T cell therapies.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • PD-L1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • NSCLC (Non-Small Cell Lung Cancer), Melanoma, Breast Cancer, Glioma, Lymphoma, Leukemia and Various Urinary Tract Tumors, Gastrointestinal Tumors, Germ Tract Tumors
  • Generation
  • 2nd-generation CAR
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ

Target

  • Clone
  • Atezolizumab
  • Host
  • Humanized
  • Target Species
  • Human
  • Gene Name
  • CD274 molecule
  • Synonyms
  • CD274; PD-L1; PDL1
  • Introduction
  • This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for TS-Fluc Anti-Human PD-L1 scFv (Atezolizumab) CD28-CD3ζ CAR, pCDCAR1 (XS-0722-YF56). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.